Recent Updates
Recently added Catalysts
ERAS Positive Sentiment Score: 75/100

Erasca to Present at the 8th Annual Evercore Healthcare Conference

Key Takeaway: Erasca, Inc. (Nasdaq: ERAS), a precision oncology company, will present at the 8th Annual Evercore Healthcare Conference on December 3, 2025. The event will take place at the Loews Coral Gables Hotel in Florida, where Erasca’s management is expected to participate in a fireside chat and one-on-one investor meetings. A live webcast of the event will be available, showcasing the company's efforts to develop therapies targeting RAS/MAPK pathway-driven cancers.

Market Sentiment Analysis

POSITIVE FACTORS

  • Erasca is participating in a significant healthcare conference, indicating engagement with investors.
  • The company's focus on RAS/MAPK pathway-driven cancers positions them well in a niche market.
  • Management is proactive in sharing their mission and insights through fireside chats and meetings.

Full Press Release Details

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 8th Annual Evercore Healthcare Conference being held at the Loews Coral Gables Hotel in Coral Gables, FL. Management will participate in a fireside chat on Wednesday, December 3, 2025, at 10:25 am Eastern Time and will also participate in one-on-one investor meetings.
A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
LifeSci Advisors, LLC

Frequently Asked Questions

What is Erasca, Inc. focused on?

Erasca, Inc. specializes in developing therapies for RAS/MAPK pathway-driven cancers.

When is Erasca's presentation at the Evercore Conference?

Erasca will present at the Evercore Conference on December 3, 2025, at 10:25 am ET.

Where can I view Erasca’s event webcast?

The event webcast can be accessed at Erasca.com/events.

How long will the event replay be available?

The archived replay of the event will be available for 30 days after the webcast.

Who co-founded Erasca, Inc.?

Erasca was co-founded by pioneers in precision oncology and RAS targeting.

Last updated: Nov 25, 2025